金城医药
(300233)
| 流通市值：69.67亿 | | | 总市值：72.25亿 |
| 流通股本：3.70亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 931,696,552.76 | 3,538,312,459.65 | 2,568,752,667.57 | 1,705,293,296.69 |
| 营业收入 | 931,696,552.76 | 3,538,312,459.65 | 2,568,752,667.57 | 1,705,293,296.69 |
| 二、营业总成本 | 824,597,996.18 | 3,293,667,808.57 | 2,386,749,531.4 | 1,570,483,289.96 |
| 营业成本 | 517,103,996.16 | 1,991,127,087.91 | 1,481,237,371.13 | 969,720,965.31 |
| 税金及附加 | 10,418,858.11 | 36,155,248.75 | 28,097,165.92 | 18,305,243.48 |
| 销售费用 | 171,862,174.54 | 680,647,573.8 | 489,839,831.89 | 315,565,703.59 |
| 管理费用 | 88,039,447.4 | 390,750,791.04 | 256,459,465.98 | 184,252,986.45 |
| 研发费用 | 37,715,121.84 | 184,708,538.25 | 121,823,184.36 | 76,204,151.74 |
| 财务费用 | -541,601.87 | 10,278,568.82 | 9,292,512.12 | 6,434,239.39 |
| 其中:利息费用 | 4,851,607.94 | 24,924,241.76 | 19,192,178.59 | 13,470,866.87 |
| 其中:利息收入 | 3,996,286.93 | 14,592,685.12 | 9,442,987.34 | 6,048,361.31 |
| 加:公允价值变动收益 | 203,056.53 | -81,540.57 | -13,411.7 | -264,453.95 |
| 加:投资收益 | -164,341.19 | 590,132.95 | -70,366.52 | -333,115.14 |
| 资产处置收益 | 173,415.58 | -2,156,299.76 | -2,611,874.47 | -2,840,726.18 |
| 资产减值损失(新) | -63,981.56 | -46,542,833.7 | -18,541,487.6 | -7,484,141.49 |
| 信用减值损失(新) | 2,270,345.38 | -4,807,335.75 | -1,839,142.59 | -987,392.27 |
| 其他收益 | 6,132,520.85 | 34,202,442.64 | 16,589,485.47 | 11,274,006.5 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 115,649,572.17 | 225,849,216.89 | 175,516,338.76 | 134,174,184.2 |
| 加:营业外收入 | 71,925.52 | 983,971.32 | 773,540.77 | 725,990.63 |
| 减:营业外支出 | 166,741.38 | 1,425,648.26 | -11,497.86 | -792,177.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 115,554,756.31 | 225,407,539.95 | 176,301,377.39 | 135,692,352.55 |
| 减:所得税费用 | 26,395,828.26 | 32,096,540.84 | 29,646,354.21 | 24,919,791.7 |
| 六、净利润 | 89,158,928.05 | 193,310,999.11 | 146,655,023.18 | 110,772,560.85 |
| 持续经营净利润 | 89,158,928.05 | 193,310,999.11 | 146,655,023.18 | 110,772,560.85 |
| 归属于母公司股东的净利润 | 82,971,349.76 | 174,709,358.21 | 132,480,355.98 | 101,709,417.13 |
| 少数股东损益 | 6,187,578.29 | 18,601,640.9 | 14,174,667.2 | 9,063,143.72 |
| (一)基本每股收益 | 0.22 | 0.45 | 0.34 | 0.26 |
| (二)稀释每股收益 | 0.22 | 0.45 | 0.34 | 0.26 |
| 八、其他综合收益 | - | 1,705,202.58 | 7,056,674.1 | 7,056,674.1 |
| 归属于母公司股东的其他综合收益 | - | 1,705,202.58 | 7,056,674.1 | 7,056,674.1 |
| 九、综合收益总额 | 89,158,928.05 | 195,016,201.69 | 153,711,697.28 | 117,829,234.95 |
| 归属于母公司股东的综合收益总额 | 82,971,349.76 | 176,414,560.79 | 139,537,030.08 | 108,766,091.23 |
| 归属于少数股东的综合收益总额 | 6,187,578.29 | 18,601,640.9 | 14,174,667.2 | 9,063,143.72 |
| 公告日期 | 2024-04-25 | 2024-03-29 | 2023-10-25 | 2023-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |